DANYA J WENZLER M.D.
Prescription History 1154511244
Internal Medicine - Infectious Disease in Randolph, NJ


Quality Rating: 82.56 out of 100 score

NPI Status: Active since July 26, 2007

Contact Information

765 ROUTE 10 E
RANDOLPH, NJ
ZIP 07869
Phone: (973) 989-0068
Fax: (973) 361-8955

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DANYA J WENZLER M.D., an active Infectious Disease specialist practicing in Randolph, NJ. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 371 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 62 claims alone.


Ampicillin Sodium

Generic Formulation: Ampicillin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 60
NJ State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.2
Peer Average Days Supply45
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,990.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$266.03

State Avg Cost Per Claim

$131.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.

Therapeutic Applications

Ampicillin is used to treat a wide variety of bacterial infections. It is a penicillin-type antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 62
30-Day Fills 62.0
Days Supply 1,860
NJ State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills76.3
Peer Average Days Supply2,279
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $253,949.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,095.96

State Avg Cost Per Claim

$3,949.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 45
30-Day Fills 45.0
Days Supply 306
NJ State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply146
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.5% higher than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,501.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$100.04

State Avg Cost Per Claim

$85.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Complera

Generic Formulation: Emtricita/Rilpivirine/Tenof DfSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NJ State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.6
Peer Average Days Supply556
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,430.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,452.58

State Avg Cost Per Claim

$3,545.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation that contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate. It is used to treat HIV INFECTIONS.

Therapeutic Applications

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Emtricitabine and tenofovir belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Rilpivirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine/rilpivirine/tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
NJ State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply999
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,522.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,306.79

State Avg Cost Per Claim

$2,171.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ertapenem

Generic Formulation: Ertapenem SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 107
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply125
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,177.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$539.82

State Avg Cost Per Claim

$529.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Therapeutic Applications

Ertapenem is used to prevent and treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Genvoya

Generic Formulation: Elviteg/Cob/Emtri/Tenof AlafenSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 810
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply951
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111,579.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,132.58

State Avg Cost Per Claim

$4,010.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Odefsey

Generic Formulation: Emtricitab/Rilpiviri/Tenof AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
NJ State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.6
Peer Average Days Supply1,007
Conservative Utilization

This provider writes prescriptions for this formulation 34.4% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77,891.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,709.13

State Avg Cost Per Claim

$3,606.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir alafenamide. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Emtricitabine and tenofovir alafenamide belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Rilpivirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine/rilpivirine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
NJ State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply961
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.8% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $37,142.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,653.03

State Avg Cost Per Claim

$2,451.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Prezista

Generic Formulation: DarunavirSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NJ State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.1
Peer Average Days Supply817
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.6% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,965.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,330.42

State Avg Cost Per Claim

$1,937.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Darunavir belongs to a class of drugs known as protease inhibitors. Darunavir must be given with certain other medications (such as cobicistat, ritonavir) to increase (boost) the levels of darunavir. This helps darunavir work better. Darunavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. This medication is not recommended for use in children younger than 3 years due to the increased risk of serious side effects.

Ritonavir

Generic Formulation: RitonavirSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
NJ State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply934
Conservative Utilization

This provider writes prescriptions for this formulation 40.7% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,851.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$115.73

State Avg Cost Per Claim

$164.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Ritonavir belongs to a class of drugs known as protease inhibitors. It increases (boosts) the levels of other protease inhibitors, which helps these medications work better. Ritonavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sodium Chloride

Generic Formulation: 0.9 % Sodium ChlorideSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 115
NJ State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.4
Peer Average Days Supply314
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $328.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.44

State Avg Cost Per Claim

$11.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).

Therapeutic Applications

This product is used to treat dryness inside the nose (nasal passages). It helps add moisture inside the nose to dissolve and soften thick or crusty mucus. In babies and young children with stuffy noses who cannot blow their noses, using this product helps to make the mucus easier to remove with a nasal bulb syringe. This helps relieve stuffiness and makes breathing easier. This product contains a purified gentle salt solution (also called saline or sodium chloride solution). It does not contain any medication.

Tigecycline

Generic Formulation: TigecyclineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 101
NJ State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$3,780.19

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia.

Therapeutic Applications

Tigecycline is used to treat certain serious bacterial infections when other antibiotics may not work. It is related to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 1,380
NJ State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.6
Peer Average Days Supply1,283
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $167,602.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,643.54

State Avg Cost Per Claim

$2,191.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Triumeq

Generic Formulation: Abacavir/Dolutegravir/LamivudiSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply958
Conservative Utilization

This provider writes prescriptions for this formulation 46.7% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,982.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,811.42

State Avg Cost Per Claim

$3,750.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 100
NJ State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply209
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $735.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.57

State Avg Cost Per Claim

$165.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DANYA J WENZLER M.D. provides transparency into local medical care patterns within Randolph, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.